Skip to main
HOWL
HOWL logo

Werewolf Therapeutics (HOWL) Stock Forecast & Price Target

Werewolf Therapeutics (HOWL) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Werewolf Therapeutics Inc. is showing significant progress in its clinical development pipeline, particularly with its WTX-330 and WTX-124 programs, which have demonstrated favorable safety profiles and promising anti-tumor activity in clinical and preclinical studies. The company's innovative PREDATOR platform enhances dosing flexibility and efficacy while mitigating systemic toxicity, which could lead to improved patient outcomes compared to traditional therapies. With continued advancements, Werewolf's technologies have the potential to expand beyond oncology into broader immune-mediated indications, positioning the company favorably within the biopharmaceutical sector.

Bears say

Werewolf Therapeutics Inc reported a significant increase in its net loss, posting $20.4 million, or $0.46 per share, in the fourth quarter of 2024, which is notably higher than the $12.0 million loss recorded in the same quarter of the previous year. Concerns arise regarding the potential challenges faced by its lead candidate, WTX-124, including the risks of clinical or regulatory setbacks and questions surrounding its safety, efficacy, and pharmacokinetic properties, which could impede its commercial viability. Furthermore, the financial outlook is overshadowed by the possibility that expansion opportunities might not be fully recognized in the company's overall valuation, raising doubts about its future revenue generation capabilities.

Werewolf Therapeutics (HOWL) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Werewolf Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Werewolf Therapeutics (HOWL) Forecast

Analysts have given Werewolf Therapeutics (HOWL) a Buy based on their latest research and market trends.

According to 8 analysts, Werewolf Therapeutics (HOWL) has a Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Werewolf Therapeutics (HOWL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.